HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Silberstein, E. B. Articles by Schnur, W. Search for Related Content PubMed PubMed Citation Articles by Silberstein, E. B. Articles by Schnur, W.

Cyclic Oral Phosphate and Etidronate Increase Femoral and Lumbar Bone Mineral Density and Reduce Lumbar Spine Fracture Rate Over Three Years

Division of Nuclear Medicine, The Jewish Hospital of Cincinnati and E. L. Saenger Radioisotope Laboratory, University of Cincinnati Medical Center, Cincinnati, Ohio

Correspondence: For reprints contact: Edward B. Silberstein, MD, Mail Location 577, University of Cincinnati Medical Center, Cincinnati, OH 45267.

ABSTRACT

We have performed a study of the safety and efficacy of cyclic sequential oral phosphate, diphosphonate and calcium carbonate. Forty-two postmenopausal women with osteoporosis diagnosed by dual-photon absorptiometry were treated with a sequential cyclic regimen of oral phosphate for 3 days, etidronate for 2 wk, and then a calcium salt for 12 wk. This was repeated cyclically for 3 yr. They were rescanned after every two 101-day cycles. A control group of 20 patient receiving only the calcium salt was matched for age, time since menopause, race and sex. The group treated with cyclic phosphate, etidronate, and calcium regimen had 80% fewer fractures than the control group over 3 yr of follow-up. Significant response in halting bone mineral loss and increasing bone mineral density was seen in none of the controls but in 90% of treated patients' lumbar spine and 70%–80% of the three regions of the femoral neck examined.

This article has been cited by other articles:

				A. Qaseem, V. Snow, P. Shekelle, R. Hopkins Jr., M. A. Forciea, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, September 16, 2008; 149(6): 404 - 415. [Abstract] [Full Text] [PDF]

				C. MacLean, S. Newberry, M. Maglione, M. McMahon, V. Ranganath, M. Suttorp, W. Mojica, M. Timmer, A. Alexander, M. McNamara, et al. Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis Ann Intern Med, February 5, 2008; 148(3): 197 - 213. [Abstract] [Full Text] [PDF]

				T Masud, B Mulcahy, A V Thompson, S Donnelly, R W Keen, D V Doyle, and T D Spector Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women Ann Rheum Dis, June 1, 1998; 57(6): 346 - 349. [Abstract] [Full Text]

				E. L. Logigian, K. A. Johnson, M. F. Kijewski, R. F. Kaplan, J. A. Becker, K. J. Jones, B. M. Garada, B. L. Holman, and A. C. Steere Reversible cerebral hypoperfusion in Lyme encephalopathy Neurology, December 1, 1997; 49(6): 1661 - 1670. [Abstract] [Full Text] [PDF]

				R. Djaldetti, J. Baron, I. Ziv, and E. Melamed Gastric emptying in Parkinson's disease: Patients with and without response fluctuations Neurology, April 1, 1996; 46(4): 1051 - 1054. [Abstract] [Full Text] [PDF]